Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

BACKGROUND The Thai phase 3 HIV vaccine trial RV 144 showed modest efficacy of a vaccine against HIV acquisition. Baseline variables of age, sex, marital status, and risk did not modify vaccine efficacy. We did a post-hoc analysis of the trial's data to investigate behavioural risk and efficacy every 6 months after vaccination. METHODS RV 144 was a randomised, multicentre, double-blind, placebo-controlled efficacy trial testing the combination of the HIV vaccines ALVAC-HIV (vCP1521) and AIDSVAX B/E to prevent HIV infection or reduce setpoint viral load. Male and female volunteers aged 18-30 years were recruited from the community. In this post-hoc analysis of the modified intention-to-treat population (16,395 participants), HIV risk behaviour was assessed with a self-administered questionnaire at the time of initial vaccination in the trial and every 6 months thereafter for 3 years. We classified participants' behaviour as low, medium, or high risk. Both the acquisition endpoint and the early viral-load endpoint were examined for interactions with risk status over time and temporal effects after vaccination. Multiple proportional hazards regression models with treatment and time-varying risk covariates were analysed. FINDINGS Risk of acquisition of HIV was low in each risk group, but 9187 (58·2%) participants reported higher-risk behaviour at least once during the study. Participants classified as high or increasing risk at least once during follow-up were compared with those who maintained low-risk or medium-risk behaviour as a time-varying covariate, and the interaction of risk status and acquisition efficacy was significant (p=0·01), with greater benefit in low-risk individuals. Vaccine efficacy seemed to peak early--cumulative vaccine efficacy was estimated to be 60·5% (95% CI 22-80) through the 12 months after initial vaccination--and declined quickly. Vaccination did not seem to affect viral load in either early or late infections. INTERPRETATION Future HIV vaccine trials should recognise potential interactions between challenge intensity and risk heterogeneity in both population and treatment effects. The regimen tested in the RV 144 phase 3 trial might benefit from extended immunisation schedules. FUNDING US Army Medical Research and Materiel Command and Division of AIDS, National Institute of Allergy and Infectious Disease, National Institutes of Health.

[1]  N. Walker,et al.  Estimation of "needs" and "probable uptake" for HIV/AIDS preventive vaccines based on possible policies and likely acceptance (a WHO/UNAIDS/IAVI study). , 2003, Vaccine.

[2]  Ting-Zhu Huang,et al.  Estimation of ||A-1||∞ and the smallest singular value , 2008, Comput. Math. Appl..

[3]  J. Moore,et al.  Viral phenotype and CCR5 genotype , 1999, Nature Medicine.

[4]  S. Plotkin,et al.  Vaccines: correlates of vaccine-induced immunity. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  B. Haynes,et al.  Low-Dose Mucosal Simian Immunodeficiency Virus Infection Restricts Early Replication Kinetics and Transmitted Virus Variants in Rhesus Monkeys , 2010, Journal of Virology.

[6]  John P. Moore,et al.  Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans , 2008, Nature Medicine.

[7]  Michael R Kosorok,et al.  Simultaneous Inferences on the Contrast of Two Hazard Functions with Censored Observations , 2002, Biometrics.

[8]  Marie-Claude Boily,et al.  HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention , 2010, International journal of epidemiology.

[9]  Norman L. Letvin,et al.  T-Cell Vaccine Strategies for Human Immunodeficiency Virus, the Virus with a Thousand Faces , 2009, Journal of Virology.

[10]  Jessica B. Graham Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial , 2012 .

[11]  Clare E. Thomas Roadblocks in HIV research: five questions , 2009, Nature Medicine.

[12]  Hui Li,et al.  Wide Variation in the Multiplicity of HIV-1 Infection among Injection Drug Users , 2010, Journal of Virology.

[13]  Marie-Claude Boily,et al.  Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. , 2009, The Lancet. Infectious diseases.

[14]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[15]  M. Hudgens,et al.  Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys , 2011, Science Translational Medicine.

[16]  M. Feinberg,et al.  Prospects for an AIDS vaccine: three big questions, no easy answers. , 2004, The Lancet. Infectious diseases.

[17]  Jerome H. Kim,et al.  Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys , 2011, Nature.

[18]  Danielle Harvey,et al.  Attenuated Poxvirus-Based Simian Immunodeficiency Virus (SIV) Vaccines Given in Infancy Partially Protect Infant and Juvenile Macaques Against Repeated Oral Challenge With Virulent SIV , 2005, Journal of acquired immune deficiency syndromes.

[19]  S. Buchbinder,et al.  Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. , 2004, The Journal of infectious diseases.

[20]  J. Lieberman,et al.  A Sound Rationale Needed for Phase III HIV-1 Vaccine Trials , 2004, Science.

[21]  Punnee Pitisuttithum,et al.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.

[22]  D. Hawkins,et al.  UK Guideline for the use of post-exposure prophylaxis for HIV following sexual exposure , 2006, International journal of STD & AIDS.

[23]  W. Phoolcharoen HIV/AIDS prevention in Thailand: success and challenges. , 1998, Science.

[24]  Alan S. Perelson,et al.  Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1 , 2009, The Journal of experimental medicine.

[25]  P. Sawanpanyalert,et al.  Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand. , 2006, Japanese journal of infectious diseases.

[26]  W. E. Rogers,et al.  Replication after Repeated Low Dose Heterologous SIV Challenge 2 , 2010 .

[27]  B. Walker,et al.  Immunology and the elusive AIDS vaccine , 2010, Nature.